Flare Risk Drops if Brensocatib Clears Key Protein from NCFBE Patient Sputum, Trial Finds
News
Adults with non-cystic fibrosis bronchiectasis (NCFBE) who were given brensocatib in a Phase 2 trial were 72% less likely to be at risk of an exacerbation if neutrophil elastase in their sputum fell to undetectable ... Read more